In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi

Gloria M. González, Annette W. Fothergill, Deanna A. Sutton, Michael G. Rinaldi, David Loebenberg

Research output: Contribution to journalArticle

83 Scopus citations


The in vitro activities of three new triazoles were determined and compared to those of itraconazole and fluconazole against 306 clinical isolates of Blastomyces dermatitidis, Cladophialophora carrionii, Coccidioides immitis, Fonsecaea pedrosoi, Fusarium spp., Histoplasma capsulatum, Paecilomyces lilacinus, Pseudallescheria boydii and Sporothrix schenckii. Minimum inhibitory concentrations (MIC) were determined by a broth macrodilution method of the National Committee for Clinical Laboratory Standards M38-A procedure. Itraconazole (geometric mean MIC, 0.16-0.65 μg/ml), voriconazole (geometric mean MIC, 0.18-1.44 μg/ml), ravuconazole (geometric mean MIC, 0.18-1.09 μg/ml), and posaconazole (geometric mean MIC, 0.18-1.38 μg/ml), had relatively uniform values showing potent in vitro inhibitory activity against B. dermatitidis, C. carrionii, C. immitis, F. pedrosoi, H. capsulatum, and S. schenckii. The in vitro activity was variable with strains of P. boydii, P. lilacinus and Fusarium spp.

Original languageEnglish (US)
Pages (from-to)281-284
Number of pages4
JournalMedical mycology
Issue number3
StatePublished - May 1 2005



  • Fluconazole
  • Itraconazole
  • Posaconazole
  • Ravuconazole
  • Voriconazole

ASJC Scopus subject areas

  • Infectious Diseases

Cite this